SRR4195677
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PROTEIN_SECRETION+0.260
- UV_RESPONSE_DN+0.250
- SPERMATOGENESIS+0.160
- HEDGEHOG_SIGNALING+0.140
- KRAS_SIGNALING_UP+0.120
- APICAL_SURFACE+0.080
- HEME_METABOLISM+0.040
- TGF_BETA_SIGNALING+0.040
- ANDROGEN_RESPONSE-0.020
- MITOTIC_SPINDLE-0.030
Top 10 suppressed
- MYC_TARGETS_V2-0.580
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.480
- CHOLESTEROL_HOMEOSTASIS-0.450
- XENOBIOTIC_METABOLISM-0.390
- UV_RESPONSE_UP-0.380
- DNA_REPAIR-0.370
- TNFA_SIGNALING_VIA_NFKB-0.370
- OXIDATIVE_PHOSPHORYLATION-0.350
- UNFOLDED_PROTEIN_RESPONSE-0.350
- MTORC1_SIGNALING-0.340
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 69550f7f-5251-4657-863b-bd35d69c82c4 | — | — | 0.924 |
| 2 | b8135e73-31c3-49af-b4da-a7ed5f28d68a | — | — | 0.917 |
| 3 | TCGA-A7-A0DB-01C-02R-A277-07 | — | D | 0.916 |
| 4 | d1447a31-64bb-4e70-ae50-eeff7a605f38 | — | — | 0.912 |
| 5 | 62454053-936d-4f19-8522-6219c47bdd1c | — | — | 0.900 |
| 6 | TCGA-A7-A13G-01B-04R-A22O-07 | — | D | 0.889 |
| 7 | TCGA-A7-A26E-01B-06R-A277-07 | — | D | 0.880 |
| 8 | ed8896f8-24ef-43a4-ace6-ed9353bd11c2 | — | — | 0.879 |
| 9 | TCGA-44-2665-01B-06R-A277-07 | — | cohortMD2 | 0.878 |
| 10 | ba2b0b86-f7f1-47f7-b0fd-bec3f623febb | — | — | 0.875 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 8 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PROTEIN_SECRETION | 0.260 | Remibrutinib | — uncovered |
| UV_RESPONSE_DN | 0.250 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.160 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.140 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.120 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.080 | Temsirolimus | — uncovered |
| HEME_METABOLISM | 0.040 | Temsirolimus | — uncovered |
| TGF_BETA_SIGNALING | 0.040 | Inavolisib | — uncovered |